About The Webinar
Mast cell tumours (MCTs) represent the full spectrum of tumour aggression from behaviourally-benign, indolent cutaneous masses to rapidly-progressive systemic disease. Predicting prognosis and choosing the correct treatment for canine MCTs is often difficult because most MCTs we see seem to lie in between these two extremes, where tumour behaviour is not "definitely good" and not "definitely bad.” In this webinar, we will explore important, and less important factors which contribute to MCT prognosis and discuss how these factors affect decision making with regard to recommending staging and treatment. Important and up-to-date treatments available to the small animal practitioner will also be discussed.
